New kidney drug QRX-3 shows promise in slowing disease progression
NCT ID NCT06948292
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed Phase 2 trial tested QRX-3, a drug that boosts NAD activity in kidney cells to reduce damage and improve function. 127 adults with chronic kidney disease stages 3-5 took part over 12 months. Researchers measured changes in kidney function and protein levels in urine to see if QRX-3 slows disease worsening compared to no treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QRX-3
- What this could lead to
- If successful, QRX-3 could offer a new way to slow kidney function decline in chronic kidney disease patients, potentially delaying the need for dialysis or transplant.
- What could go wrong
- This is a Phase 2 trial with 127 participants, so results are preliminary. The drug may not show significant benefit over placebo, and long-term safety is not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGES 3-5 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Neukidney Inc
Pasedena, Texas, 77504, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may predict rapid kidney decline in diabetes
- Blood test could flag rapid kidney failure risk in diabetes
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Could your blood type predict kidney treatment success?
- One infusion, two targets: a uric-acid-lowering drug takes aim at heart and kidney disease in youth-onset diabetes